FDA Releases First-Ever Draft Guidance For Psychedelics Research, Days After Congressional Lawmakers File Bill Asking For It

Live and Awake in LA

Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.

DEA Calls For Increased Production Of Some Psychedelics For Research, As Marijuana Quotas Level Out Ahead Of Scheduling Decision

The Drug Enforcement Administration (DEA) has released new quotas for the production of Schedule I and Schedule II controlled substances for research purposes‚Äîcalling for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA. As DEA prepares to [‚Ä¶]

Psychedelic therapy data “speaks for itself,” VA official says

The VA‚Äôs top health official said the agency is prepared to spend ‚Äúat least in the millions‚Äù on clinical trials of psychedelic therapies for PTSD.

Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote

Following last week‚Äôs negative headlines, we review how Lykos Therapeutics unsuccessfully sought to reassure the committee, how its apparent policy of minimal engagement might have backfired‚Ä¶

Bipartisan Congressional Lawmakers Tell VA To Prepare Plan For MDMA-Assisted Therapy As FDA Considers Approving The Psychedelic

Bipartisan congressional lawmakers are asking the U.S. Department of Veterans Affairs (VA) to produce a plan to begin providing MDMA-assisted therapy for veterans as soon as the psychedelic is approved by the Food and Drug Administration (FDA). In a letter sent to VA Under Secretary Shereef Elnahal on Tuesday, Reps. Morgan McGarvey (D-KY), Morgan Luttrell [‚Ä¶]